NeurAxis Stock Rallies 26% as Adoption of Drug-Free IB-Stim Technology to Treat Pediatric FAP/IBS Gains Momentum ($NRXS)
NeurAxis Inc. stock is in rally mode, jumping over 26% since last week. Despite this significant increase, investors following this innovative biotech anticipate further growth. That optimism is...
United States Rob Goldman Jack Enterprises Goldman Smallcap Research Hawk Point Media Group Llc Neuraxis Inc
Source: marketscreener.com